Three or more weeks of oral anticoagulation (OAC) sometimes isn't up to the job of clearing any potentially embolic left atrial (LA) thrombi before procedures like cardioversion or catheter ablation ...
Midland Daily News on MSN
MyMichigan Health: What to know about atrial fibrillation - signs, risks and treatment options
Lu Chen, M.D., is a cardiologist specializing in electrophysiology with MyMichigan Physicians Group.
NOAH-AFNET 6 trial: Oral anticoagulation not recommended for patients with atrial high rate episodes
Blood thinners (anticoagulants) cause bleeding without preventing stroke in patients with atrial high rate episodes (AHRE), but without electrocardiogram (ECG)-diagnosed atrial fibrillation, according ...
Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. Whether the occurrence of ...
When your electrical system is working normally, the two upper chambers of the heart (atria) contract and pump blood into the two lower chambers (ventricles) in a well-coordinated way. This results in ...
In patients with device-detected atrial fibrillation and a high comorbidity burden, oral anticoagulation increases bleeding without a clear reduction in stroke. This is the main finding of a ...
It is not correct to treat atrial fibrillation (Afib) and atrial flutter as equivalent risk factors for ischemic stroke, a Taiwanese cohort study suggested. From individuals included in the Taiwan ...
Patients with atrial fibrillation receiving routine medical care within a large managed care organization were found to have suboptimal anticoagulation control. Retrospective cross-sectional study of ...
Background Endurance exercise training produces multiple cardiac adaptations including changes in electrophysiological function that may make endurance-trained athletes more vulnerable to atrial ...
Hosted on MSN
Anticoagulation offers no clear benefit in patients with device-detected atrial fibrillation
A Win Ratio analysis confirmed the primary result of the NOAH—AFNET 6 trial and did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with device-detected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results